Optimization of THP-1-CAR monocytes utilizing CD32a signaling phagocytosis for antigen-specific T cell activation - PubMed
3 months ago
- #Phagocytosis
- #Immunotherapy
- #CAR-M therapy
- CAR-M (Chimeric Antigen Receptor Macrophages) are emerging as a next-generation therapy for viral infections and solid tumors.
- CAR constructs with CD32a signaling domains showed superior phagocytic capacity compared to CD3ζ in THP-1-derived monocytes and macrophages.
- Combining CR3 and CD32a domains increased pro-inflammatory cytokine expression (IL-1β, IL-6, TNF-α) but did not enhance phagocytosis.
- TLR4 signaling domain reduced CAR expression and phagocytosis but significantly increased inflammatory cytokine production.
- CAR-monocytes induced antigen-specific CD8+ T cell activation via antigen presentation post-phagocytosis.
- CD32a-based and combinatorial ICD designs are promising for CAR-M platforms in solid tumor immunotherapy and anti-viral applications.